GlassScriptPhysician profile
Puran Karra
NPI 1083940019
$802.35
in general payments reported to CMS, 2019-2025
16 companies · $548 in 2025
The $548 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.99 · 2020: $20.47 · 2024: $212 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $208.55 | 2024-2025 | |
| Corcept Therapeutics | $146.76 | 2024-2025 | Korlym |
| Vanda Pharmaceuticals INC. | $85.69 | 2025 | Fanapt |
| Pfizer INC. | $48.98 | 2020-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.25 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $38.58 | 2019-2024 | Breztri |
| Pulmonx Corporation | $37.71 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Axsome Therapeutics, INC. | $33.88 | 2024 | Auvelity |
| Verona Pharma, INC. | $26.22 | 2025 | Ohtuvayre |
| Lundbeck LLC | $23.51 | 2025 | Rexulti |
| Exact Sciences Corporation | $21.32 | 2025 | Cologuard Collection Kit |
| Genzyme Corporation | $20.35 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.60 | 2025 | Xifaxan |
| Optinose US, INC. | $19.52 | 2024 | |
| Sumitomo Pharma America, INC. | $18.64 | 2024 | Gemtesa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13.79 | 2024 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puran Karra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.